OpGen, Inc. (OPGN) Given Consensus Rating of “Strong Buy” by Brokerages
Shares of OpGen, Inc. (NASDAQ:OPGN) have been given an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.
Brokerages have set a 12-month consensus price objective of $1.50 for the company and are forecasting that the company will post ($0.06) EPS for the current quarter, according to Zacks. Zacks has also assigned OpGen an industry rank of 177 out of 265 based on the ratings given to related companies.
A number of research firms have recently issued reports on OPGN. Zacks Investment Research downgraded OpGen from a “buy” rating to a “hold” rating in a research note on Wednesday, September 13th. HC Wainwright restated a “buy” rating and issued a $1.00 price target on shares of OpGen in a research note on Monday, September 11th.
A hedge fund recently raised its stake in OpGen stock. Vanguard Group Inc. boosted its stake in shares of OpGen, Inc. (NASDAQ:OPGN) by 1.6% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 342,860 shares of the medical research company’s stock after purchasing an additional 5,500 shares during the period. Vanguard Group Inc. owned about 1.25% of OpGen worth $219,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 12.21% of the company’s stock.
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.